Rare Disease Registries: Practical Ways to Build Trust with Patient Advocacy Groups

With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.

1:02:03

The changing face of cell and gene therapy Impacts on planning and executing trials

32:11

Rare Disease Registries: Practical Ways to Build Trust with Patient Advocacy Groups

With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.

1:02:03

Reflections on paediatric assent: Have we outgrown this concept?

In this webinar, medical ethicists will discuss what investigators, ethics committees, IRBs and – ideally – sponsors can do to reverse this trend and create documents which achieve their intended purpose of allowing a child to understand their trial.

1:02:52

Rare Disease Registries: Practical Ways to Build Trust with Patient Advocacy Groups

With the right planning and understanding, collaboration between drug development companies and patient advocacy groups (PAGs) can be mutually beneficial in a number of key areas.

1:02:03

The importance of early planning in cell & gene therapy commercialization

1:01:11